Innate Pharma Sa Class A · EURONEXT:IPH
Innate Pharma Sa Class A — Jefferies Healthcare Conference 2025
26 slides from Innate Pharma Sa Class A's conference presentation, Nov 17, 2025
Slide 1: Company overview
Company overview Jefferies Healthcare Conference 2025 London, November 17, 2025
Slide 2: Disclaimer
Disclaimer This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document contains certain forward-looking statements, including those wi
Slide 3: Strategic Overview and Outlook
Strategic Overview and Outlook 3
Slide 4: Leveraging our scientific know-how to advance life-enhancing cancer therapy candidates
Leveraging our scientific know-how to advance life-enhancing cancer therapy candidates Expertise in antibody- Clinical pipeline High value assets with engineering to drive focused on high unmet near-term commercial innovation medical need potential Strong fundamentals in antibody Advancing a portfol
Slide 5: Delivering on our strategic priorities and driving value through focused execution
Delivering on our strategic priorities and driving value through focused execution Clinical programs Research Organization Focus investment Advance our next Streamline the on highest-value ADCs toward organization clinical assets development IPH4502 Multiple programs Fit-for-purpose Lacutamab organi
Slide 6: Driving growth through our lead clinical programs
Driving growth through our lead clinical programs LACUTAMAB MONALIZUMAB IPH4502 Anti-KIR3DL2 mAb in CTCL Anti-NKG2A mAb in NSCLC Nectin-4 ADC in solid tumors Phase 3 in preparation Phase 3 ongoing Phase 1 ongoing • First-in-class KIR3DL2 depleting mAb • PACIFIC-9 Phase 3 in unresectable • Novel and
Slide 7: IPH4502: Novel and differentiated DAR8 Nectin-4 exatecan ADC
IPH4502 Novel and differentiated DAR8 Nectin-4 exatecan ADC 7
Slide 8: Nectin-4 expression in solid tumors
IPH4502 Nectin-4 expression in solid tumors 100 No Nectin-4 drug approved PADCEV (enfortumab vedotin, EV) is approved 01 solely for patients with urothelial cancer, where % of Nectin-4 expressing 80 expression of Nectin-4 is the highest tumor samples 60 PADCEV induced toxicity frequently leads to 02
Slide 9: IPH4502: Novel and differentiated DAR8 Nectin-4 exatecan ADC
IPH4502 IPH4502: Novel and differentiated DAR8 Nectin-4 exatecan ADC Target profile Binder Linker Payload Proprietary humanized anti-Nectin-4 antibody Cleavable Exatecan, a topoisomerase I inhibitor • High affinity • Hydrophilic → improved half-life, low clearance • Active in EV/MMAE-resistant model
Slide 10: IPH4502 preclinical activity supporting opportunity in post-Padcev bladder cancer and multiple solid tumors
IPH4502 IPH4502 preclinical activity supporting opportunity in post-Padcev bladder cancer and across multiple solid tumors with low-to-medium Nectin-4 expression Bladder cancer Multiple solid tumors Post-Padcev setting Low-to-medium Nectin-4 expression Vehicle IPH4502 4 mg/kg IPH4502 10 mg/kg EV 4 m
Slide 11: A First-in-Human Phase 1 clinical trial evaluating IPH4502 in solid tumors
IPH4502 A First-in-Human Phase 1 clinical trial evaluating IPH4502 in solid tumors A Phase 1, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of IPH4502 as a Single Agent in Advanced Solid Tumors (NCT06781983) STUDY POPULATION Dose escalation Dose optimization OBJECTIVES n=
Slide 12: Lacutamab, anti-KIR3DL2 Ab
Lacutamab, anti-KIR3DL2 Ab Lead proprietary antibody progressing towards potential accelerated approval and Phase 3 initiation 12
Slide 13: Lacutamab: from niche market entry to broader opportunity
lacutamab Lacutamab: from niche market entry to broader opportunity Phase 3 in preparation Phase 3 in preparation Phase 2 ongoing BLA filing planned based on Phase 2 data once Phase 3 is underway 03 02 PTCL 01 Aggressive lymphoma with poor CTCL Mycosis Fungoides (MF) prognosis and high unmet need CT
Slide 14: Lacutamab shows clinical benefit in Sézary syndrome
lacutamab Lacutamab shows clinical benefit in Sézary syndrome, an aggressive subtype of CTCL with limited treatment option Global ORR = 42.9% (31.4-55.1) Long term follow up data from the TELLOMAK Phase 2 trial Data cut-off (DCO): OCT 17, 2024 63 patients with ≥2 prior lines of systemic therapy, pos
Slide 15: In mycosis fungoides, lacutamab shows robust clinical activity regardless of KIR3DL2 expression
lacutamab In mycosis fungoides, lacutamab shows robust clinical activity regardless of KIR3DL2 expression level Global ORR = 19.6% (13.2, 28.1) KIR3DL2 ≥ 1% (N=48) KIR3DL2 <1% (N=59) Long term follow up data from the ORR 20.8%(11.7 - 34.3) ORR 18.6% (10.7 – 30.4) TELLOMAK Phase 2 trial Data cut-off
Slide 16: FDA clearance to proceed with TELLOMAK-3 Phase 3 trial in CTCL
lacutamab FDA clearance to proceed with TELLOMAK-3, a confirmatory phase 3 trial of lacutamab in CTCL Open-label, multi-center, randomized comparative Phase 3 study of lacutamab in R/R patients with MF or SS Primary Key Secondary Endpoint Endpoints Lacutamab KEY ELIGIBILITY SS Cohort Randomization P
Slide 17: Focused opportunity in specialized centers treating SS and MF
lacutamab Focused opportunity in specialized centers treating SS and MF Sezary Syndrome (SS) Mycosis Fungoides (MF) Near-term Phase 3 objective is to establish Lacutamab De-risked opportunity in the US as the new 2L standard of care • Higher incidence from real-world data1 than public • Higher incid
Slide 18: Lacutamab market potential in CTCL
lacutamab Lacutamab market potential in CTCL Patient Incidence Up to $150m* Up to $500m** >$500m** # Expand use of CTCL systemic therapy for Market 1L Systemic therapy early-stage and expansion other CTCL patients Mycosis Mycosis 2L fungoides fungoides Sezary Sezary Sezary 3L+ syndrome syndrome synd
Slide 19: Monalizumab: Co-developed with AstraZeneca, Phase 3 PACIFIC-9 trial ongoing in NSCLC
Monalizumab Co-developed with AstraZeneca, Phase 3 PACIFIC-9 trial ongoing in NSCLC Monalizumab is an investigational antibody under clinical evaluation. It is not approved for any indication, and its safety and efficacy have not been established. 19
Slide 20: PACIFIC-9: Phase III trial in unresectable stage III NSCLC
monalizumab PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer ✓ Three Phase 2 Trials supporting rationale of combination in early NSCLC (COAST, NeoCOAST, NeoCOAST-2) ✓ Phase 3 PACIFIC-9 trial fully recruited, IDMC recommended the
Slide 21: COAST phase 2 study of durvalumab with oleclumab or monalizumab
monalizumab COAST is a global, open-label, phase 2 study of durvalumab alone or combined with the anti-CD73 monoclonal antibody (mAb) oleclumab or anti-NKG2A mAb monalizumab as consolidation therapy • PACIFIC trial established consolidation durvalumab after chemoradiotherapy (CRT) as the standard of
Slide 22: Financial highlights of the partnership with AstraZeneca on monalizumab
monalizumab Financial highlights of the partnership with AstraZeneca on monalizumab Amounts received Total amount of the agreement: 1.275 billion US$ Total milestones Milestone Initial payments 250 100 payments Development and regulatory 50 50 400 In US$ million Commercialization 425 Royalties Outsi
Slide 23: Key takeaways and near term catalysts
Key takeaways and near term catalysts 23
Slide 24: Driving growth through our lead clinical programs
Driving growth through our lead clinical programs IPH4502 LACUTAMAB MONALIZUMAB Nectin-4 ADC in solid tumors Anti-KIR3DL2 mAb in CTCL Anti-NKG2A mAb in NSCLC Phase 1 ongoing Phase 3 in preparation Phase 3 ongoing • Pharmacologically active dose • FDA clearance to proceed with • PACIFIC-9 Phase 3 in
Slide 25: Strong short-term catalysts across Innate's portfolio
Strong short-term catalysts across Innate’s portfolio 2026 H1 2026 H2 ≥ 2027 IPH4502 Lacutamab AA in SS Phase 1 Data Monalizumab Monalizumab BLA Phase 3 AZ PACIFIC-9 Lacutamab IPH4502 Ph1/2 Data readouts Ph3 TELLOMAK-3 Initiation Expansion cohorts data AA: accelerated approval; SS: Sézary syndrome;
Slide 26: Thank you
EURONEXT : IPH.PA NASDAQ : IPHA Thank you www.innate-pharma.com investors@innate-pharma.fr 26